Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,395 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05765825 | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC | active not recruiting | Phase 2 | 61 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer(MOZART) | recruiting | Phase 2 | 84 | Hirva MamdaniOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)(DeLLphi-306) | active not recruiting | Phase 3 | 404 | AmgenINDUSTRY | 27 | Apr 29, 2026 | clinicaltrials |
| NCT06477523 | Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC | active not recruiting | Phase 1 / Phase 2 | 57 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC | withdrawn | Phase 1 | 0 | Sichuan UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT01744249 | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | completed | Phase 2 / Phase 3 | 256 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Apr 28, 2026 | clinicaltrials |
| NCT06889493 | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | recruiting | Phase 1 | 36 | Peter Hosein, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | recruiting | Phase 1 | 100 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01916148 | 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07243132 | Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)(LUNGEVITY) | recruiting | — | 1,000 | GFPC InvestigationOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | not yet recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06536868 | Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC | recruiting | Phase 2 | 40 | Second Hospital of Shanxi Medical UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06736418 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | active not recruiting | Phase 1 | 17 | Abdera Therapeutics Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 2 / Phase 3 | 298 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550049 | Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology(COMETH) | not yet recruiting | — | 110 | University of Kansas Medical CenterOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07550842 | A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 33 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05617963 | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax(DURVALUNG) | active not recruiting | Phase 2 | 100 | UNICANCEROTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07547332 | Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC | not yet recruiting | Phase 2 | 84 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07548788 | A Lay Navigation Intervention for Patients With Lung Cancer | not yet recruiting | N/A | 50 | University Health Network, TorontoOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04349436 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies(ARTACUS) | active not recruiting | Phase 1 / Phase 2 | 69 | Replimune, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04701307 | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07247526 | Effect of Foot Bath on Anxiety and Physiological Parameters | completed | N/A | 100 | Trakya UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04074135 | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 740 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538258 | Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer(Aurora004) | not yet recruiting | Phase 2 | 27 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07538271 | A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer(Aurora 005) | not yet recruiting | Phase 2 | 33 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06500026 | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | active not recruiting | Phase 3 | 722 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07536087 | Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors | recruiting | N/A | 50 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT07532057 | The Effect of Pulmonary Rehabilitation on Pulmonary Function Tests, Exercise Capacity, and Quality of Life in Patients With Advanced-Stage Lung Cancer Receiving Chemotherapy(PR-LUNGCA-2019) | completed | N/A | 30 | Istanbul Medipol University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07534371 | Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study | active not recruiting | — | 500 | West China HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05153772 | Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients(ALPHAMEDIX02) | active not recruiting | Phase 2 | 69 | Orano Med LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05470595 | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung(LCNEC-ALPINE) | active not recruiting | Phase 2 | 67 | Technische Universität DresdenOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04375267 | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours(LuPARP) | completed | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | recruiting | — | 90 | Medical University of BialystokOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01163383 | 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol | available | — | — | John MarisOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03540420 | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer(ACHILES) | active not recruiting | Phase 2 | 212 | Norwegian University of Science and TechnologyOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05249114 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors | active not recruiting | Phase 1 | 6 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05595460 | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | active not recruiting | Phase 1 | 21 | RayzeBio, Inc.INDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT06753136 | Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype | recruiting | N/A | 24 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06893783 | Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients(DeLLight) | recruiting | Phase 2 | 60 | Inkeun ParkOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07501169 | Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)(STAR-01) | not yet recruiting | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04291885 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma(I-MAT) | active not recruiting | Phase 2 | 122 | Melanoma and Skin Cancer Trials LimitedOTHER | 2 | Apr 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2026source: clinicaltrials